Grace Chao
Grace Chao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Bolaender
Eli Lilly and Company, Indianapolis, Indiana
21 shared publications - David Bauer
Department of Radiology, Memorial Sloan Kettering Cancer Center
21 shared publications - Edwin Charles Pratt
Memorial Sloan Kettering Cancer Center 1 Molecular Pharmacology Department New York, New York
21 shared publications - Emily C. Collins
Eli Lilly and Company, Indianapolis, Indiana
21 shared publications - Jason S. Lewis
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
21 shared publications - Mark A. Castanares
Eli Lilly and Company, Indianapolis, Indiana
21 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
[64Cu]Cu-Trop-2.2 imaging to confirm Trop-2 positivity before tandem therapy and at end of study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
[64Cu]Cu-Trop-2.2 imaging to confirm Trop-2 positivity before tandem therapy and at end of study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes, weights, and IHC for fractionated 212Pb-Trop-2.2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes, weights, and IHC for fractionated 212Pb-Trop-2.2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Practical considerations to 212Pb production via extraction chromatography
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Practical considerations to 212Pb production via extraction chromatography
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Purpose:Trophoblast cell surface antigen-2 (Trop-2) is a membrane-bound antigen associated with cancer invasiveness and poorer patient outcomes. Delivery of therapeutics via Trop-2 targeting antibody–drug conjugates (ADC) has proven to be a viable and FDA-approved model. However, in the clinic, ADC dosing is not based on Trop-2 positivity or expression, leading to potential adverse effects if the antigen membrane level on cancer cells is insufficient for targeting. The challenge of adequate patient and therapy selection can be overcome by leveraging the theranostic approach. We previously established a Trop-2.2 antibody for immunoPET imaging, allowing us to theoretically select patients with positive Trop-2 lesions.Experimental Design:In this work, the antibody Trop-2.2 was repurposed for lutetium-177, actinium-225, and lead-212 radiotherapies. We explored the benefits of direct, tandem, pretargeted, and fractionated approaches to radiopharmaceutical dosing.Results:Therapy with the α emitter 225Ac regressed tumors, with eight out of 10 mice alive after 150 days. Alternatively, 212Pb, a shorter-lived in vivo α generator therapeutic, was found to be more effective when harnessing the pretargeting (PreT) strategy compared with a directly labeled approach. Our in-house 212Pb production allowed us to investigate fractionated dosing on a weekly basis. Fractionation resulted in tumor reductions through 12 weeks of therapy with minimal and reversible blood toxicity for the lowest dose. With repeat administrations, we found pathologically significant renal and ovarian toxicity attributable to 212Pb administration but an otherwise effective PreT method.Conclusions:In this study, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2–expressing pancreatic cancer model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Purpose:Trophoblast cell surface antigen-2 (Trop-2) is a membrane-bound antigen associated with cancer invasiveness and poorer patient outcomes. Delivery of therapeutics via Trop-2 targeting antibody–drug conjugates (ADC) has proven to be a viable and FDA-approved model. However, in the clinic, ADC dosing is not based on Trop-2 positivity or expression, leading to potential adverse effects if the antigen membrane level on cancer cells is insufficient for targeting. The challenge of adequate patient and therapy selection can be overcome by leveraging the theranostic approach. We previously established a Trop-2.2 antibody for immunoPET imaging, allowing us to theoretically select patients with positive Trop-2 lesions.Experimental Design:In this work, the antibody Trop-2.2 was repurposed for lutetium-177, actinium-225, and lead-212 radiotherapies. We explored the benefits of direct, tandem, pretargeted, and fractionated approaches to radiopharmaceutical dosing.Results:Therapy with the α emitter 225Ac regressed tumors, with eight out of 10 mice alive after 150 days. Alternatively, 212Pb, a shorter-lived in vivo α generator therapeutic, was found to be more effective when harnessing the pretargeting (PreT) strategy compared with a directly labeled approach. Our in-house 212Pb production allowed us to investigate fractionated dosing on a weekly basis. Fractionation resulted in tumor reductions through 12 weeks of therapy with minimal and reversible blood toxicity for the lowest dose. With repeat administrations, we found pathologically significant renal and ovarian toxicity attributable to 212Pb administration but an otherwise effective PreT method.Conclusions:In this study, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2–expressing pancreatic cancer model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
[89Zr]Zr-DFO-Trop-2.2 PET/CT and CLI of a mouse with an odontogenic tumor
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
[89Zr]Zr-DFO-Trop-2.2 PET/CT and CLI of a mouse with an odontogenic tumor
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Biolayer interferometry, radiolabeling and biodistribution outcome with increased chelator burden
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Biolayer interferometry, radiolabeling and biodistribution outcome with increased chelator burden
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Pathology 1 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Supplementary pathology description of therapy studies
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Pathology 1 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Supplementary pathology description of therapy studies
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes and weights for 212Pb and 225Ac pretargeting and preclicked tandem therapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes and weights for 212Pb and 225Ac pretargeting and preclicked tandem therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes and weights for 177Lu and 225Ac therapy with Trop-2.2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Tumor volumes and weights for 177Lu and 225Ac therapy with Trop-2.2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Clinical blood chemistry and rodent chemistry panel values for select mice submitted to pathology provided as a separate SI dataset for ease of reading
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Trop-2.2–Directed Radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a Pancreatic Cancer Model
Clinical blood chemistry and rodent chemistry panel values for select mice submitted to pathology provided as a separate SI dataset for ease of reading